Panelists discuss how, as new data on cemiplimab and other checkpoint inhibitors emerge, the treatment pathway for cancers ...

Panelists discuss how, cemiplimab, a PD-1 inhibitor, has shown promise as a second-line therapy for advanced NSCLC after ...

The PD-L1 IHC 22C3 PharmDx (Code SK006) assay is now certified for use to aid treatment decisions for patients with gastric or gastroesophageal junction adenocarcinoma.

Regeneron's oncology platform is poised to be a significant growth driver in the next decade. Read why REGN stock remains a ...

The Nonmelanoma Skin Cancer market is expected to experience substantial growth from 2024 to 2034, driven by increasing ...

Findings from a phase 1 trial demonstrate that silmitasertib shows potential for the treatment of patients with advanced ...

The vast majority of Medicare's top-selling brand-name oncology drugs in 2022 provided high added therapeutic benefit. Ten drugs were classified as low or no added therapeutic benefit compared ...

and cemiplimab (Libtayo), an anti–PD-1 agent, in patients with advanced melanoma. 1 The first-in-human, phase 1, open-label, dose-escalation and cohort expansion trial sought to evaluate the safety ...

Therefore, Senhwa will actively pursue licensing possibilities while carefully evaluating CX-4945's potential as a monotherapy or in combination with the second-line immunotherapy Libtayo. The company ...

The U.S. Food and Drug Administration (FDA) has approved three immunotherapy medications to treat adults with advanced squamous cell skin cancer: Cemiplimab-rwlc improves the immune system’s ability ...